Preexisting TP53 mutation in therapy-related acute myeloid leukemia

Annals of Hematology

Volumn 94, Issue 3, 2015, Pages 527-529

  Schulz, Eduard ^a   Kashofer, Karl ^a   Heitzer, Ellen ^a   Mhatre, Ketaki N ^a   Speicher, Michael R ^a   Hoefler, Gerald ^a   Sill, Heinz ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Leukemogenesis; Therapy related myeloid neoplasms; TP53

Indexed keywords

PROTEIN P53; TP53 PROTEIN, HUMAN;

ACUTE MYELOBLASTIC LEUKEMIA; AGED; CASE REPORT; GENETIC PREDISPOSITION; GENETICS; HODGKIN DISEASE; HUMAN; MALE; MUTATION; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; SECOND CANCER;

AGED; DNA MUTATIONAL ANALYSIS; GENETIC PREDISPOSITION TO DISEASE; HODGKIN DISEASE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MUTATION; NEOPLASMS, SECOND PRIMARY; POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84939895440     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-014-2191-0     Document Type: Letter

References (8)

1. Churpek JE, Larson RA (2013) The evolving challenge of therapy-related myeloid neoplasms. Best Pract Res Clin Haematol 26(4):309–317. doi:10.1016/j.beha.2013.09.001
2. Vardiman JW, Arber DA, Brunning RD, Larson RA, Matutes E, Baumann I et al (2008) Therapy-related myeloid neoplasms. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H (eds) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. IARC, Lyon, pp 127–129
3. Mauritzson N, Albin M, Rylander L, Billstrom R, Ahlgren T, Mikoczy Z, Bjork J, Stromberg U, Nilsson PG, Mitelman F, Hagmar L, Johansson B (2002) Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976–1993 and on 5098 unselected cases reported in the literature 1974–2001. Leukemia 16(12):2366–2378. doi:10.1038/sj.leu.2402713
4. Wong TN, Ramsingh G, Young A, Shen D, Miller C, Lamprecht T, Heath S, Fulton RS, Mardis ER, Ding L, Westervelt P, Welch J, Walter MJ, Graubert T, DiPersio JF, Ley TJ, Druley TE, Wilson RK, Link DC (2013) The role of early TP53 mutations on the evolution of therapy-related AML. Blood 122(21):5
5. Shih AH, Chung SS, Dolezal EK, Zhang SJ, Abdel-Wahab OI, Park CY, Nimer SD, Levine RL, Klimek VM (2013) Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia. Haematologica 98(6):908–912. doi:10.3324/haematol.2012.076729
6. Schulz E, Valentin A, Ulz P, Beham-Schmid C, Lind K, Rupp V, Lackner H, Wolfler A, Zebisch A, Olipitz W, Geigl J, Berghold A, Speicher MR, Sill H (2012) Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms. J Med Genet 49(7):422–428. doi:10.1136/jmedgenet-2011-100674
7. Zhao Z, Zuber J, Diaz-Flores E, Lintault L, Kogan SC, Shannon K, Lowe SW (2010) P53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. Genes Dev 24(13):1389–1402. doi:10.1101/gad.1940710
8. Cancer Genome Atlas Research Network (2013) Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 368(22):2059–2074. doi:10.1056/NEJMoa1301689